GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (SHSE:688185) » Definitions » Other Operating Expense

CanSino Biologics (SHSE:688185) Other Operating Expense : ¥-107.3 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CanSino Biologics Other Operating Expense?

CanSino Biologics's Other Operating Expense for the three months ended in Dec. 2024 was ¥0.0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was ¥-107.3 Mil.

CanSino Biologics's quarterly Other Operating Expense declined from Mar. 2024 (¥30.4 Mil) to Jun. 2024 (¥-62.3 Mil) but then increased from Jun. 2024 (¥-62.3 Mil) to Dec. 2024 (¥0.0 Mil).

CanSino Biologics's annual Other Operating Expense declined from Dec. 2022 (¥-61.0 Mil) to Dec. 2023 (¥-82.9 Mil) but then increased from Dec. 2023 (¥-82.9 Mil) to Dec. 2024 (¥-57.5 Mil).


CanSino Biologics Other Operating Expense Historical Data

The historical data trend for CanSino Biologics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Other Operating Expense Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only -82.86 -14.99 -60.97 -82.95 -57.46

CanSino Biologics Quarterly Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.42 -88.96 30.45 -62.25 -

CanSino Biologics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-107.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CanSino Biologics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.

CanSino Biologics Headlines

No Headlines